India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

AU Small Finance Bank: The First Graduate from India's SFB Sector

From Gas to Coal: The Hidden Hedge in Energy Markets

2026 High Conviction Ideas: Does the IndiGo Crisis Offer an Entry Point, or Confirms Caution?

The Beat Ideas: Dixon Technologies ~ Revival or Ruin?

Glenmark’s R&D Leap: How a Large Biotech Liscensing Deal with AbbVie Could Change Its Fortune

The Beat Ideas: Meesho Ltd- Deciphering India’s Value-E-Commerce Giant

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Glenmark Pharmaceuticals / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/glenmark-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:10454:1" rel="noopener">Glenmark Pharmaceuticals (GNP IN)</a> is executing a strategic "3.0" transformation into a science-led innovator, following a landmark $1.925 billion AbbVie partnership.</li>
<li>Q2 India sales fell 87% due to GST-related distributor inventory rationalization, with normalized revenue recovery of INR 1,150–1,200 crore expected from Q3. 
</li>
<li>Management targets 15% annual revenue growth and 25% EBITDA margins by FY27, supported by a zero-gross-debt balance sheet.</li>
</ul>



Glenmark Pharmaceuticals (GNP IN) is executing a strategic "3.0" transformation into a science-led innovator, following a landmark $1.925 billion AbbVie partnership.
Q2 India sales fell 87% due to GST-related distributor inventory rationalization, with normalized revenue recovery of INR 1,150–1,200 crore expected from Q3. 

Management targets 15% annual revenue growth and 25% EBITDA margins by FY27, supported by a zero-gross-debt balance sheet.


Glenmark Pharmaceutical Ltd ~ Ambitious Guidance or Realistic Roadmap?